• JXY, TLR4, and M1 Polarization in Colitis-Associated CRC

  2026-10-06

  The 2024 study by Liu et al. investigates how Jiedu Xiaozheng Yin limits colitis-associated colorectal cancer by shifting intestinal macrophages toward an M1-associated phenotype through TLR4-linked signaling. Its main contribution is the integration of tumor, tissue, immune-phenotype, and pathway-interrogation evidence, although the findings remain primarily preclinical and do not establish clinical efficacy or a fully resolved molecular mechanism.

• Tianhuang Formula and RAGE/POMC Metabolic Signaling

  2026-10-06

  The 2026 study identifies RAGE as a central nervous system target of berberine within Tianhuang Formula and links RAGE/POMC signaling with hypothalamic neuronal apoptosis, autophagy, and glucolipid metabolism. Its integrated computational, biochemical, cellular, and animal evidence supports a mechanistic hypothesis, while the lack of direct RAGE-loss-of-function experiments limits causal and clinical interpretation.

• Adefovir (GS-0393): From HBV Potency to OAT1

  2026-10-05

  A translational view of Adefovir as both an HBV DNA polymerase inhibitor and a renal OAT1 probe, integrating mechanistic rationale, population pharmacokinetic evidence, study-design priorities, and the boundaries of current evidence.

• LY2886721: BACE1 Inhibition and Evidence

  2026-10-05

  LY2886721 is a BACE inhibitor used to study amyloid precursor protein processing and amyloid beta reduction. Available evidence supports target engagement in biochemical, cellular, and mouse models, while rat-neuron data show that the biological effects of BACE1 enzyme inhibition depend on the degree of amyloid reduction.

• P2Y2 Signaling and Aβ42 Uptake by Microglia

  2026-10-04

  Kim et al. show that fibrillar and oligomeric Aβ1–42 stimulate nucleotide release from mouse microglia, linking local extracellular ATP or UTP signaling to microglial migration, Aβ uptake, and degradation through P2Y2 receptors. The study is important because it frames Aβ clearance as a coordinated paracrine response rather than only a direct interaction between microglia and amyloid.

• Iptacopan: From Factor B Biology to Evidence

  2026-10-03

  Iptacopan (LNP023) selectively targets factor B to clarify alternative complement pathway biology. This article adds an evidence-calibration framework, connecting complement readouts with prediction-model principles without confusing mechanistic activity with clinical effectiveness.

• Hydroxychloroquine Sulfate Workflow Guide

  2026-10-02

  Hydroxychloroquine Sulfate (SKU B4874) provides an aqueous-compatible research tool for examining TLR7/9 signaling and autophagy pathway modulation in autoimmune disease research. It is best suited to controlled, short-term water-based workflows and should not be selected for DMSO- or ethanol-based stocks or long-term storage of prepared solutions.

• Amyloid β-Peptide (1-42) (human) Guide

  2026-10-01

  A scenario-based laboratory guide to using Amyloid β-Peptide (1-42) (human), SKU B6057, in neuronal viability, cytotoxicity, and ion-channel studies. It connects published SH-SY5Y findings with practical preparation, controls, interpretation, and product-selection decisions that support more reproducible Alzheimer's disease research.

• LNP Surface Charge and V-ATPase in Nucleic Acid Delivery

  2026-10-01

  The reference study proposes that lipid nanoparticle surface charge and target-cell V-ATPase activity jointly shape functional nucleic acid delivery. Its in vitro and in vivo experiments link this interaction to liver or lung tropism and identify endo/lysosomal function as a target-side variable that may complement conventional LNP design.

• Stat3, Fyn, and Dopaminergic Neurodegeneration

  2026-09-30

  Siddiqui and colleagues used a neural-specific zebrafish model of constitutively active Fyn to show that Stat3 contributes to dopaminergic neuron loss and microglial inflammatory activation. Live imaging, transcriptomics, and pathway inhibition place Stat3 alongside NF-κB as a mechanistic link between Fyn signaling, neuroinflammation, and neurodegeneration.

• Caspase-3/7 Inhibitor I: Mechanism and Use

  2026-09-30

  Caspase-3/7 Inhibitor I is a reversible, cell-permeable isatin sulfonamide that preferentially inhibits caspase-3 and caspase-7. Its selectivity and cellular apoptosis-blocking data make it a useful mechanistic control for caspase activity measurement, while pathway-specific interpretation still requires orthogonal readouts.

• Gamma-linolenic Acid: Assay Workflows

  2026-09-29

  Gamma-linolenic acid (GLA) supports practical inflammation, lipid-signaling, and cell-death studies through complementary receptor-binding and cellular readouts. This guide connects product handling with reproducible workflows while separating established GLA evidence from emerging immune-adjuvant questions raised by recent arachidonic acid research.

• Acetoacetic acid sodium salt: Workflow Guide

  2026-09-29

  Acetoacetic acid sodium salt provides a water-compatible, defined ketone-body perturbation for energy metabolism research and diabetes-focused assay development. This guide combines practical dosing, matrix-aware controls, and isotope-informed analytical validation to improve reproducibility without treating an exploratory reagent as a clinical surrogate.

• Cy3-UTP for Fluorescent RNA Labeling

  2026-09-28

  Cy3-UTP is a Cy3-modified uridine triphosphate for producing fluorescent RNA during in vitro transcription. Its reported water solubility, 95% purity, and light-protected storage requirement support imaging, RNA-protein interaction studies, and RNA detection assay workflows when appropriate controls are used.

• Sulfamonomethoxine Toxicity Across Aquatic Trophic Levels

  2026-09-28

  Huang and colleagues tested sulfamonomethoxine (SMM) across algae, cladocerans, and medaka, extending aquatic toxicity evidence beyond a single organism group. Their reported results identify microalgae as more sensitive than cladocerans in the assays summarized, while also showing why endpoint, exposure duration, and species must be considered when interpreting ecological risk.

8091 records 1/540 page Next 12345 下5页 Last page